First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy

NEXT STORY
Medigene Provides Results for Fiscal Year 2019 and Outlook
PREV STORY
Urinalysis Market Worth $2.21 billion by 2027- Exclusive Report by Meticulous Research®
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

World Conference on Lung Cancer Wednesday Press Conference: Applying Conference Discoveries and Themes to the Real World

TORONTO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- The final press briefing from the International ...

author_avatar
NASDAQ Market News

Roche’s Alecensa (alectinib) significantly reduced the risk of disease worsening or death as first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer

Head-to-head phase III study of Alecensa versus crizotinib in Asian patient population showed a ...

author_avatar
NASDAQ Market News

Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell

UTRECHT, The Netherlands, May 15, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage ...

author_avatar
NASDAQ Market News